• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

是否在手术或有创操作之前检测直接口服抗凝药物的水平,这是一个棘手的问题。

The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

机构信息

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Maggiore Hospital Foundation, Via Pace 9, 20122, Milan, Italy.

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

出版信息

Intern Emerg Med. 2018 Oct;13(7):1029-1036. doi: 10.1007/s11739-018-1854-6. Epub 2018 Apr 26.

DOI:10.1007/s11739-018-1854-6
PMID:29700696
Abstract

Direct oral anticoagulants (DOAC) possess high bioavailability, and their anticoagulant effect is more predictable than that of vitamin K antagonists, hence they do not require routine dose adjustment based on laboratory testing. However, there are circumstances when laboratory testing may be useful, including patients who need to undergo surgery or invasive procedures. Most guidelines state that patients on DOAC may safely undergo surgery/invasive procedures by stopping anticoagulation for a few days before intervention without testing if renal function is within normal limits. This review article discusses the pros and cons of measuring (or not measuring) DOAC levels before surgery/invasive procedures by a multidisciplinary team of experts with different background, including the thrombosis laboratory, clinical thrombosis, internal medicine, cardiology and nephrology. The conclusion is that measuring DOAC with dedicated tests before surgical or invasive procedures is important for patient safety. It provides the best and most direct evidence to rule in (or to rule out) clinically relevant concentrations of residual drugs. Regulatory agencies should urgently approve their use in clinical practice. Hospital administrators should make them available, and clinical laboratories should set up the relative methods and make them available to clinicians.

摘要

直接口服抗凝剂(DOAC)具有生物利用度高的特点,其抗凝效果比维生素 K 拮抗剂更可预测,因此无需根据实验室检测结果常规调整剂量。然而,在某些情况下,实验室检测可能会很有用,包括需要接受手术或有创操作的患者。大多数指南指出,如果肾功能正常,DOAC 患者在接受干预前停止抗凝治疗几天,而无需进行检测,就可以安全地接受手术/有创操作。本文由来自血栓实验室、临床血栓形成、内科、心脏病学和肾脏病学等不同背景的多学科专家团队讨论了在手术/有创操作前测量(或不测量)DOAC 水平的利弊。结论是,在手术或有创操作前使用专用检测方法测量 DOAC 对患者安全很重要。它为是否存在有临床意义的残留药物浓度提供了最佳和最直接的证据。监管机构应紧急批准其在临床实践中的使用。医院管理者应确保其供应,临床实验室应建立相关方法并向临床医生提供。

相似文献

1
The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.是否在手术或有创操作之前检测直接口服抗凝药物的水平,这是一个棘手的问题。
Intern Emerg Med. 2018 Oct;13(7):1029-1036. doi: 10.1007/s11739-018-1854-6. Epub 2018 Apr 26.
2
Direct oral anticoagulants: When to consider laboratory testing?直接口服抗凝剂:何时考虑实验室检测?
Int J Lab Hematol. 2018 May;40 Suppl 1:30-33. doi: 10.1111/ijlh.12816.
3
[New oral anticoagulants (NOAC) in nephrology].
G Ital Nefrol. 2016 Jul-Aug;33(4).
4
[Anticoagulation-direct oral anticoagulants].[抗凝治疗——直接口服抗凝剂]
Internist (Berl). 2017 Jun;58(6):585-597. doi: 10.1007/s00108-017-0243-y.
5
Laboratory Assessment of Direct Oral Anticoagulants.直接口服抗凝剂的实验室评估
Semin Thromb Hemost. 2017 Apr;43(3):277-290. doi: 10.1055/s-0036-1597296. Epub 2017 Mar 1.
6
Direct Oral Anticoagulants in Emergency Trauma Admissions.急诊创伤入院患者中的直接口服抗凝剂
Dtsch Arztebl Int. 2016 Sep 5;113(35-36):575-82. doi: 10.3238/arztebl.2016.0575.
7
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.长期接受直接口服抗凝剂治疗的患者的手术和有创操作:凝血酶或因子 Xa 抑制剂。围手术期止血工作组和法国血栓与止血研究组的建议。
Arch Cardiovasc Dis. 2011 Dec;104(12):669-76. doi: 10.1016/j.acvd.2011.09.001. Epub 2011 Oct 29.
8
Direct Oral Anticoagulants: Monitoring Anticoagulant Effect.直接口服抗凝剂:监测抗凝效果。
Hematol Oncol Clin North Am. 2016 Oct;30(5):995-1006. doi: 10.1016/j.hoc.2016.05.004.
9
[Management of direct oral anticoagulants for invasive procedures].
J Mal Vasc. 2015 May;40(3):173-81. doi: 10.1016/j.jmv.2015.02.004. Epub 2015 Mar 14.
10
Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.直接口服抗凝剂的实验室检测:临床实践中的指征及对管理的影响
Int J Lab Hematol. 2017 May;39 Suppl 1:31-36. doi: 10.1111/ijlh.12654.

引用本文的文献

1
Navigating anemia and anticoagulation in elderly patients undergoing orthopedic surgery: strategies for preventing complications and implementing treatments.老年骨科手术患者的贫血与抗凝问题管理:预防并发症与实施治疗的策略。
Blood Transfus. 2024 Sep;22(5):450-458. doi: 10.2450/BloodTransfus.640. Epub 2024 May 6.
2
Management of patients with proximal femur fractures under DOACs.接受直接口服抗凝剂治疗的股骨近端骨折患者的管理
Eur J Trauma Emerg Surg. 2024 Apr;50(2):359-366. doi: 10.1007/s00068-024-02472-4. Epub 2024 Feb 24.
3
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study.

本文引用的文献

1
Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.实验室间直接口服抗凝剂测量的变异性:来自外部质量评估计划的结果。
J Thromb Haemost. 2018 Mar;16(3):565-570. doi: 10.1111/jth.13949. Epub 2018 Jan 29.
2
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.直接口服抗凝剂患者择期手术或操作的围手术期抗凝使用评估(PAUSE)研究:设计与原理。
Thromb Haemost. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553. Epub 2017 Dec 6.
3
极低和高体重患者直接口服抗凝剂的治疗药物监测——初步研究
J Clin Med. 2023 Jul 28;12(15):4969. doi: 10.3390/jcm12154969.
4
Review of perioperative outcomes and management of hip fracture patients on direct oral anticoagulants.直接口服抗凝剂治疗的髋部骨折患者围手术期结局及管理的综述
EFORT Open Rev. 2023 Jul 3;8(7):561-571. doi: 10.1530/EOR-22-0060.
5
Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.印度非维生素K拮抗剂口服抗凝剂(NOACs)使用的专家建议:当前观点与未来方向
Cardiol Ther. 2022 Mar;11(1):49-79. doi: 10.1007/s40119-022-00254-w. Epub 2022 Feb 8.
6
Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease.静脉血栓栓塞性疾病患者对抗凝治疗的特征及偏好
Front Cardiovasc Med. 2021 Jun 21;8:675969. doi: 10.3389/fcvm.2021.675969. eCollection 2021.
7
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.关于直接口服抗凝剂在慢性肾脏病患者中的安全性/疗效特征的立场文件。来自 SIN、FCSA 和 SISET 的共识文件。
Blood Transfus. 2020 Nov;18(6):478-485. doi: 10.2450/2020.0156-20. Epub 2020 Aug 6.
8
Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).直接口服抗凝剂在慢性肾脏病患者中的安全性/疗效概况立场文件:意大利肾脏病学会(SIN)、血栓诊断和抗血栓治疗监测中心联合会(FCSA)和意大利止血与血栓形成研究学会(SISET)的共识文件。
J Nephrol. 2021 Feb;34(1):31-38. doi: 10.1007/s40620-020-00768-3. Epub 2020 Jul 31.
9
Direct oral anticoagulants in lipoprotein apheresis: handle with care.脂蛋白分离术中的直接口服抗凝剂:谨慎使用。
Intern Emerg Med. 2019 Oct;14(7):1171-1173. doi: 10.1007/s11739-019-02118-z. Epub 2019 Jun 4.
10
A focus on direct oral anticoagulants: "old" and possible new indications and efforts for a better clinical management.聚焦直接口服抗凝剂:“旧”有及可能的新适应症以及改善临床管理的努力。
Intern Emerg Med. 2018 Oct;13(7):985-988. doi: 10.1007/s11739-018-1954-3. Epub 2018 Sep 21.
Heart Failure and Kidney Disease.
心力衰竭与肾脏病。
Adv Exp Med Biol. 2018;1067:219-238. doi: 10.1007/5584_2017_126.
4
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.直接口服抗凝剂患者实验室检测立场文件。SISET、FCSA、SIBioC 和 SIPMeL 的共识文件。
Blood Transfus. 2018 Sep;16(5):462-470. doi: 10.2450/2017.0124-17. Epub 2017 Sep 13.
5
Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.依达肝素浓度的测定:蛇静脉酶凝血活酶时间与稀释凝血酶时间检测比较。
J Thromb Haemost. 2017 Dec;15(12):2377-2387. doi: 10.1111/jth.13857. Epub 2017 Oct 30.
6
Italian intersociety consensus on DOAC use in internal medicine.意大利内科医学领域关于直接口服抗凝剂(DOAC)使用的跨学会共识。
Intern Emerg Med. 2017 Apr;12(3):387-406. doi: 10.1007/s11739-017-1628-6. Epub 2017 Feb 13.
7
DOACs - advances and limitations in real world.直接口服抗凝剂——现实世界中的进展与局限
Thromb J. 2016 Oct 4;14(Suppl 1):17. doi: 10.1186/s12959-016-0111-3. eCollection 2016.
8
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply.术前或侵入性操作前是否检测直接口服抗凝剂:回复
J Thromb Haemost. 2016 Dec;14(12):2559-2561. doi: 10.1111/jth.13513. Epub 2016 Oct 24.
9
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment.术前或侵入性操作前是否检测直接口服抗凝剂:评论
J Thromb Haemost. 2016 Dec;14(12):2556-2559. doi: 10.1111/jth.13505. Epub 2016 Oct 24.
10
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.在接受直接口服抗凝剂治疗的患者中,凝血筛选试验与特定检测方法的可比性较差:一项多中心/多平台研究的结果。
J Thromb Haemost. 2016 Nov;14(11):2194-2201. doi: 10.1111/jth.13486. Epub 2016 Oct 15.